Integrated or stand alone Drug Discovery services (from hit findings to IND), to discover and evaluate the therapies of tomorrow together.
A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation
Value creation through innovative technologies & R&D partnerships
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
For Oncodesign, artificial intelligence (AI) is a powerful tool for accelerating and making drug development more reliable.
Optimization of data use to enhance and accelerate Drug Discovery processes in oncology
For more than 25 years, Oncodesign has been investing in precision medicine innovation technologies, which are essential from the very first stages of the Drug Discovery process.
Oncodesign’s mission is to discover new innovative therapies that are effective against cancers and serious diseases with no known treatments.
| Broker | Analyst | Recommandation | TARGET PRICE |
 | Gilbert Ferrand | *buy | 20€ |
 | Fanny Meindre | **buy | 15€ |
 | Victor Floc’h | *na | 15€ |
 | Christophe Dombu | *strong buy | 16.4€ |
*Recommendations given November 3 and 4, 2020.
** Recommandations given June, 23, 2021.
18 rue Jean Mazen - FR - 21000 Dijon
Tel.+33 380 788 260
Receive our general letter or our financial news!
